Latest news with #SASS
United News of India
20-05-2025
- United News of India
Electric shock from water tap, woman Ayyappa devotee from Telangana dies at Pamba
Sabarimala, May 20 (UNI) In a shocking incident, a 60-year-old woman Ayyappa devotee was electrocuted to death while trying to open a drinking water tap at Pamba, leading to protest by Sabarimala Ayyappa Seva Samajam (SASS) demanding a probe into the incident and compensation for the victim from Telangana. SASS National Chairman SJR Kumar has strongly condemned the incident and demanded an immediate and thorough probe into the cause of the tragic loss of life. "The unfortunate incident occurred when she attempted to open the drinking water tap in shed number two while returning after Darshan at the Lord Ayyappa temple in Sabarimala on Monday evening. Despite being rushed to Pampa Hospital, her life could not be saved." "It is unlikely that a normal 220V supply would result in such a sudden death, raising serious concerns about a potential surge in the electric supply. This needs to be investigated urgently," he said. The SASS also calls for an inquiry into whether immediate and timely first aid and medical assistance were provided, which could have potentially averted this tragic outcome. The victim was identified as E. Bharathamma, a resident of Gopalpet Mandal, Mahabubnagar, Telangana. Considering the financially vulnerable background of the deceased, whose husband passed away 25 years ago, leaving behind a son and a daughter dependent on her, the Sabarimala Ayyappa Seva Samajam demands that the bereaved family be provided with suitable compensation. The Samajam also urged the concerned authorities to take immediate and necessary steps to prevent any such occurrences and negligence in Sabarimala in the future, ensuring the safety and well-being of all pilgrims. He also demanded a probe by a team of expert engineers from the Kerala Electrical Inspectorate to determine whether the Travancore Devaswom Board or the Kerala State Electricity Board (KSEB) is responsible for the electrical installations at the site. He also condoled the tragic death of the devotee and conveyed his deep sympathies to her grieving family. UNI DS BD
Yahoo
08-04-2025
- Business
- Yahoo
Apnimed doses first subject in trial for sleep apnoea with central component
US-based Apnimed has dosed the first subject in the multi-centre Phase IIA RESTEADY trial of SASS-001, an oral drug combo for sleep apnoea with a central component. SASS-001 is a combination of selective P2X3 receptor antagonist, sivopixant, and another compound. The randomised, controlled, dose-escalation, double-blind, parallel-arm trial is intended for underserved individuals with this condition. It aims to enrol about 60 subjects at up to ten clinical sites in the US. Subjects are set to be randomised to a dose-escalating arm of the therapy or a placebo arm. They will take part in the trial for a ten-week period, with study measures including sleep-clinic polysomnography as well as at-home sleep assessments. SASS-001 comes from Apnimed's joint venture (JV) with Shionogi, named Shionogi-Apnimed Sleep Science (SASS), as its first clinical-stage asset. The JV aims at expediting the discovery, preclinical and clinical development of pharmacologic solutions for addressing the pathology of sleep apnoea and other sleep-related conditions. Apnimed CEO Larry Miller said: 'With the first patient dosed in the Phase IIA RESTEADY trial, both Apnimed and SASS have reached an important milestone – the advancement of a scientific hypothesis to clinical development. 'Today's announcement represents the combined efforts of the Apnimed and Shionogi teams, highlighting their respective strengths in sleep medicine drug development and drug discovery.' In parallel, AD109, the company's clinical programme, is advancing after the enrolment conclusion in its Phase III trials, LunAIRo and SynAIRgy, with these trials' top-line data expected in the second and third quarters of this year, respectively. AD109 is under evaluation in obese and non-obese adults with mild, moderate, and severe obstructive sleep apnoea (OSA). In May 2023, the company reported positive outcomes from the MARIPOSA Phase IIb trial of AD109 for the treatment of OSA. "Apnimed doses first subject in trial for sleep apnoea with central component" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
08-04-2025
- Business
- Yahoo
Apnimed doses first subject in trial for sleep apnoea with central component
US-based Apnimed has dosed the first subject in the multicentre Phase IIA RESTEADY trial of SASS-001, an oral drug combo for sleep apnoea with a central component. SASS-001 is a combination of selective P2X3 receptor antagonist, sivopixant, and another compound. The randomised, controlled, dose-escalation, double-blind, parallel-arm trial is intended for underserved individuals with this condition. It aims to enrol about 60 subjects at up to ten clinical sites in the US. Subjects are set to be randomised to a dose-escalating arm of the therapy or a placebo arm. They will take part in the trial for a ten-week period, with study measures including sleep-clinic polysomnography as well as at-home sleep assessments. SASS-001 comes from Apnimed's joint venture (JV) with Shionogi, named Shionogi-Apnimed Sleep Science (SASS), as its first clinical-stage asset. The JV aims at expediting the discovery, preclinical and clinical development of pharmacologic solutions for addressing the pathology of sleep apnoea and other sleep-related conditions. Apnimed CEO Larry Miller said: 'With the first patient dosed in the Phase IIA RESTEADY trial, both Apnimed and SASS have reached an important milestone – the advancement of a scientific hypothesis to clinical development. 'Today's announcement represents the combined efforts of the Apnimed and Shionogi teams, highlighting their respective strengths in sleep medicine drug development and drug discovery.' In parallel, AD109, the company's clinical programme, is advancing after the enrolment conclusion in its Phase III trials, LunAIRo and SynAIRgy, with these trials' top-line data expected in the second and third quarters of this year, respectively. AD109 is under evaluation in obese and non-obese adults with mild, moderate, and severe obstructive sleep apnoea (OSA). In May 2023, the company reported positive outcomes from the MARIPOSA Phase IIb trial of AD109 for the treatment of OSA. "Apnimed doses first subject in trial for sleep apnoea with central component" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
21-03-2025
- Politics
- Yahoo
Secret Service Eyes New 6.5mm Semi-Automatic Sniper Rifle
The U.S. Secret Service is looking at replacing its 7.62x51mm M110 designated marksman rifles with a new gun chambered to fire the 6.5mm Creedmoor round. A 6.5mm Creedmoor rifle would offer greater range, as well as improved accuracy and terminal performance at long distances. The Secret Service published a contracting notice seeking information about potential 6.5 Creedmoor rifles to supplant its M110s earlier today. The M110, also known as the Semi-Automatic Sniper System (SASS), is a variant of the SR-25 from Knight's Armament Company (KAC). It is in widespread use across the U.S. government, including with all branches of the U.S. military. SR-25-series rifles, which are also in service with various military and security forces globally, are notably used by spotters alongside shooters with bolt-action sniper rifles in Secret Service counter-sniper (CS) teams. 'The USSS-Office of Training has a need to replace its inventory of, M110 SASS rifle systems, to better serve our Agency's needs,' according to the contracting notice. 'The USSS-Office of Training aims to purchase up to one hundred and fifty (150) rifles to support operational and training requirements throughout the life of this contract to the USSS, and other Department of Homeland Security (DHS) components, via a multi-year Firm Fixed Price Contract vehicle.' 'The USSS Office of Training develops and implements a broad range of weapons training programs on a continuous basis, since the James J Rowley Training Center (JJRTC) trains all special agents and Uniformed Division officers,' the notice adds. An attached set of requirements call for a gas-operated semi-automatic 6.5mm Creedmoor rifle with a barrel length between 15.5 and 16.5 inches, an overall length of no more than 40 inches with a collapsible stock in its shortest position, and a weight no greater than 9.5 pounds with a sound suppressor (but not other accessories) fitted. For comparison, an M110 with a standard 20-inch barrel is 40.5 inches overall and tips the scales at just over 17.4 pounds with its sound suppressor and scope, according to the U.S. Army. The requirements say the gun can use either the direct impingement method of gas operation or a gas piston. Direct impingement, which is how the M110 works, involves propellant gas siphoned off from the barrel during firing blowing directly into the main action to cycle it. A piston system keeps the gas, and particulate matter within it, away from a gun's core components. This, in turn, reduces the chance of fouling and offers other advantages when it comes to ease of maintenance and overall reliability. Besides a need to be able to accept a suppressor, either screwed directly onto the barrel or attached via quick-detach mount, no other explicit accessory requirements are included in the contracting notice. The factory Semi-Automatic Sniper System configuration for the M110 includes a scope and bipod, as well as a suppressor and various other accessories. The rifles can also be equipped with night vision and thermal imagers, laser aiming devices, and laser range-finders. Though it has a smaller bullet, 6.5mm Creedmoor uses a modified version of the same cartridge case as the NATO-standard 7.62x51mm round. This has long made it easier to adapt existing 7.62x51mm rifles to fire 6.5mm Creedmoor, and there are various rifles on the market now that could meet the Secret Service's requirements. This includes variants and derivatives of the Armalite AR-10, as well as related designs like KAC's SR-25-series (which is more of a scaled-up derivative of the 5.56x45mm AR-15/M16 pattern that was originally scaled down from the AR-10). In addition to new-build rifles, KAC offers 6.5mm Creedmoor caliber conversion kits for existing M110s, which could be an attractive option for the Secret Service. As already noted, 6.5mm Creedmoor rifles offer better range, accuracy, and terminal performance over comparable 7.62x51mm types. The U.S. special operations community has already been leading a push to adopt 6.5mm Creedmoor rifles, as well as light machine guns, in recent years for exactly these reasons. U.S. Special Operations Command has said in the past that rifles chambered in 6.5mm Creedmoor could double a shooter's probability of scoring a hit on targets up to 3,280 feet away (1,000 meters). The stated effective range of an M110 is just under 2,625 feet (800 meters), per the Army. Accuracy and terminal performance are of particular interest to the Secret Service, which is charged with protecting the president and vice president of the United States, and their families, as well as a host of other top-tier VIPs. The critical importance of this mission was underscored by the attempted assassination of then-candidate Donald Trump last year, which was foiled by CS team members, as you can read more about here. Last year, the Secret Service also announced it was looking to buy new bolt-action sniper rifles that could be configured to fire one of four different cartridges: .300 Winchester Magnum, .300 Norma Magnum, .300 Precision Rifle Cartridge (PRC), and .308 Winchester. The primary sniper rifle for CS teams is currently a .300 Winchester Magnum bolt-action type that is very similar to the Mk 13 Mod 7 previously in service with the U.S. Marine Corps. New 6.5mm Creedmoor designated marksman rifles offering greater range, accuracy, and ballistic performance over existing M110s now also look to be on the horizon for the Secret Service. Contact the author: joe@
Yahoo
29-01-2025
- Business
- Yahoo
DeepSeek's AI breakthrough bypasses industry-standard CUDA, uses Nvidia's assembly-like PTX programming instead
When you buy through links on our articles, Future and its syndication partners may earn a commission. DeepSeek made quite a splash in the AI industry by training its Mixture-of-Experts (MoE) language model with 671 billion parameters using a cluster featuring 2,048 Nvidia H800 GPUs in about two months, showing 10X higher efficiency than AI industry leaders like Meta. The breakthrough was achieved by implementing tons of fine-grained optimizations and usage of Nvidia's assembly-like PTX (Parallel Thread Execution) programming instead of Nvidia's CUDA, according to an analysis from Mirae Asset Securities Korea cited by @Jukanlosreve. What You Need to Know Today: OpenAI boss Sam Altman calls DeepSeek 'impressive.' In 2023 he called competing nearly impossible. Jan. 28, 2025: Investors panic: Nvidia stock loses $589B in value. Dec. 27, 2024: DeepSeek is unveiled to the world. Nvidia's PTX (Parallel Thread Execution) is an intermediate instruction set architecture designed by Nvidia for its GPUs. PTX sits between higher-level GPU programming languages (like CUDA C/C++ or other language frontends) and the low-level machine code (streaming assembly, or SASS). PTX is a close-to-metal ISA that exposes the GPU as a data-parallel computing device and, therefore, allows fine-grained optimizations, such as register allocation and thread/warp-level adjustments, something that CUDA C/C++ and other languages cannot enable. Once PTX is into SASS, it is optimized for a specific generation of Nvidia GPUs. For example, when training its V3 model, DeepSeek reconfigured Nvidia's H800 GPUs: out of 132 streaming multiprocessors, it allocated 20 for server-to-server communication, possibly for compressing and decompressing data to overcome connectivity limitations of the processor and speed up transactions. To maximize performance, DeepSeek also implemented advanced pipeline algorithms, possibly by making extra fine thread/warp-level adjustments. These modifications go far beyond standard CUDA-level development, but they are notoriously difficult to maintain. Therefore, this level of optimization reflects the exceptional skill of DeepSeek's engineers. The global GPU shortage, amplified by U.S. restrictions, has compelled companies like DeepSeek to adopt innovative solutions, and DeepSeek has made a breakthrough. However, it is unclear how much money DeepSeek had to invest in development to achieve its results. The breakthrough disrupted the market as some investors believed that the need for high-performance hardware for new AI models would get lower, hurting the sales of companies like Nvidia. Industry veterans, such as Intel Pat Gelsinger, ex-chief executive of Intel, believe that applications like AI can take advantage of all computing power they can access. As for DeepSeek's breakthrough, Gelsinger sees it as a way to add AI to a broad set of inexpensive devices in the mass market.
